The most robust study of the anticancer activity of PT against lung cancer to date examined PT in combination with Osimertinib against five EGFR-mutation positive non-small cell lung cancer (NSCLC) cell lines. This evidence concerns the gene EGFR and non-small cell lung carcinoma.